Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: OBSERVATIONAL
Official Title: Open Label, Single-cohort, and Single-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients With S�zary Syndrome at Single-cell Resolution
Brief Summary: The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment.
15 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months.
Each patient will donate 5 samples to determine immune responses in peripheral blood.
Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and 6.
A CT scan will be obtained at baseline and only repeated if pathology is present at baseline.
The tumor microenvironment will be studied by comparing transcriptomics of the blood samples before, 1 day after first ECP treatment, cycle 1, 1, 3 and 6 months after ECP treatment by scRNAseq (5 samples total per patient ).